Universität zu Köln

Striefler, Jana Kaethe, Riess, Hanno, Lohneis, Philipp, Bischoff, Sven, Kurreck, Annika, Modest, Dominik Paul, Bahra, Marcus, Oettle, Helmut, Sinn, Marianne, Blaeker, Henrik, Denkert, Carsten, Stintzing, Sebastian ORCID: 0000-0002-3297-5801, Sinn, Bruno Valentin and Pelzer, Uwe (2021). Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. Front. Oncol., 11. LAUSANNE: FRONTIERS MEDIA SA. ISSN 2234-943X

Full text not available from this repository.

Abstract

Background The Mucin-family protein, MUC1, impacts on carcinogenesis and tumor invasion. We evaluated the impact of MUC1 expression on outcome in a cohort of 158 patients with resected pancreatic ductal adenocarcinomas (PDAC) in the CONKO-001 study (adjuvant gemcitabine [gem] vs. observation [obs]). Methods The percentage of MUC1-positive tumor cells by immunohistochemistry (IHC) and the staining intensity were evaluated by two observers blinded to outcome. The numeric values of both parameters were multiplied, resulting in an immunoreactivity score (IRS) ranging from 0 to 12. The level of MUC1 expression was defined as follows: IRS 0-4 (low) vs IRS >4 (high). Outcomes in terms of disease-free (DFS) and overall survival (OS) were evaluated by Kaplan-Meier method, log-rank tests and Cox regressions. Results In total, tumors of 158 study patients were eligible for immunohistochemistry of MUC1. High cytoplasmic MUC1 expression was associated with impaired DFS and OS in the overall study population (hazard ratio (HR) for DFS: 0.49, 95% CI 0.31 to 0.78, p = .003; HR for OS: 0.46, 95% CI 0.29 to 0.73, p = .001). In the study arms, prognostic effects of MUC1 were also evident in the observation group (HR for DFS: 0.55; 95% CI 0.29 to 1.04, p = .062; HR for OS: 0.34, 95% CI 0.17 to 0.67, p = .001) and trending in the gem group (HR for DFS: 0.48, 95% CI 0.24 to 0.95, p = .041; HR for OS: 0.56, 95% CI 0.28 to1.11, p = .093). Conclusion Our data suggest that MUC1 expression is a powerful prognostic marker in patients with PDAC after curatively intended resection.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Striefler, Jana Kaethe UNSPECIFIED UNSPECIFIED UNSPECIFIED Riess, Hanno UNSPECIFIED UNSPECIFIED UNSPECIFIED Lohneis, Philipp UNSPECIFIED UNSPECIFIED UNSPECIFIED Bischoff, Sven UNSPECIFIED UNSPECIFIED UNSPECIFIED Kurreck, Annika UNSPECIFIED UNSPECIFIED UNSPECIFIED Modest, Dominik Paul UNSPECIFIED UNSPECIFIED UNSPECIFIED Bahra, Marcus UNSPECIFIED UNSPECIFIED UNSPECIFIED Oettle, Helmut UNSPECIFIED UNSPECIFIED UNSPECIFIED Sinn, Marianne UNSPECIFIED UNSPECIFIED UNSPECIFIED Blaeker, Henrik UNSPECIFIED UNSPECIFIED UNSPECIFIED Denkert, Carsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Stintzing, Sebastian UNSPECIFIED orcid.org/0000-0002-3297-5801 UNSPECIFIED Sinn, Bruno Valentin UNSPECIFIED UNSPECIFIED UNSPECIFIED Pelzer, Uwe UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-596085
DOI:	10.3389/fonc.2021.670396
Journal or Publication Title:	Front. Oncol.
Volume:	11
Date:	2021
Publisher:	FRONTIERS MEDIA SA
Place of Publication:	LAUSANNE
ISSN:	2234-943X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ADJUVANT CHEMOTHERAPY; OPEN-LABEL; GEMCITABINE; CANCER; EXPRESSION; MUC1; SUBTYPES; PHASE-3 Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/59608